Protocol Ledger

NCT05522231 · Phase II/III · COMPLETED

Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)

Interventional Phase II/III clinical trial protocol NCT05522231 sponsored by Hutchmed in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-10-27 Enrollment: 265 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05522231
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)265 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05522231
Protocol FieldVerified Registry Value
NCT IdentifierNCT05522231
Consolidated Lead SponsorHutchmed
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusCOMPLETED
Registered Enrollment265 participants (ACTUAL)
Registered Start Date2022-10-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI